Home Cart Sign in  
Chemical Structure| 1638750-95-4 Chemical Structure| 1638750-95-4

Structure of ADU-S100 disodium salt
CAS No.: 1638750-95-4

Chemical Structure| 1638750-95-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ADU-S100 disodium salt is a STING activator exhibiting significant antitumor and immunomodulatory activity, suitable for cancer immunotherapy research.

Synonyms: ML RR-S2 CDA disodium salt; MIW815 disodium salt; 2'3'-c-di-AM(PS)2(Rp,Rp)disodium salt

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ADU-S100 disodium salt

CAS No. :1638750-95-4
Formula : C20H24N10Na2O10P2S2
M.W : 736.52
SMILES Code : O[C@H]1[C@]2([H])[C@H](N3C4=NC=NC(N)=C4N=C3)O[C@]1([H])CO[P@@](S)(O[C@]5([H])[C@@](O[C@@H](N6C7=NC=NC(N)=C7N=C6)[C@@H]5O)([H])CO[P@@](S)(O2)=O)=O.[Na].[Na]
Synonyms :
ML RR-S2 CDA disodium salt; MIW815 disodium salt; 2'3'-c-di-AM(PS)2(Rp,Rp)disodium salt
MDL No. :MFCD32215340

Safety of ADU-S100 disodium salt

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived dendritic cells (BMDCs) 25 μM 24 hours To verify if S100 could upregulate Tim-3 expression on cDC2, results showed that S100 significantly upregulated Tim-3 expression PMC10526657
CD4+ T cells 25 μM 3-5 days To assess the impact of Tim-3+ cDC2 on CD4+ T cell proliferation, results showed that Tim-3+ cDC2 inhibited CD4+ T cell proliferation PMC10526657
KPC1242 cells 100 mg 24 hours Evaluate the effect of ADU-S100 on pancreatic cancer cells, results showed that ADU-S100 can inhibit tumor growth and activate iμMune responses. PMC8081932

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 4T1 and B16F1 tumor models Intratumoral injection 20 mg/kg/d once daily until endpoint To evaluate the anti-tumor efficacy of S100 combined with αTim-3, results showed that the combination therapy significantly delayed tumor growth and prolonged survival PMC10526657
C57BL/6 mice peritoneal carcinomatosis model intraperitoneal injection 30 mg/kg Twice daily for 5 days The STING agonist significantly reduced peritoneal tumor nodules and suppressed the accumulation of malignant ascites, while reducing CD31+ vascular density and increasing NG2+ pericyte coverage, indicating tumor vascular normalization. Additionally, STING activation increased the number of intratumoral CD11c+ dendritic cells, CD8+ T cells, and granzyme B (GzB)-expressing T cells, suggesting activation of both innate and adaptive immunity in peritoneal tumors. PMC8215239
Mice Opioid-induced acute itch and chronic itch models Intraperitoneal injection 50 μg (first week), then reduced to 30 μg Every 2 days until tumor volume reached 2000 mm³ ADU-S100 significantly reduced opioid-induced acute itch and dermatitis-induced chronic itch behaviors PMC10150483
mice neuropathic pain models (SNI and CCI) intrathecal injection 20 mg/kg Single administration ADU-S100 significantly alleviated neuropathic pain in male mice, but not in female mice. PMC11034751
Mice Pancreatic cancer model Intratumoral injection 160 mg/kg Lopinavir + 40 mg/kg Ritonavir twice daily for two days Evaluate the antitumor effect of ADU-S100 in a pancreatic cancer model, results showed that ADU-S100 can inhibit tumor growth and activate systemic antitumor immune responses. PMC8081932
Mice Prostate cancer model Intratumoral injection 80/20 mg/kg Once daily for 4 days ADU-S100 combined with cyto-IL-15 significantly reduced tumor volume and increased survival in mice, with complete tumor regression observed in some mice. PMC10350564

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.36mL

0.27mL

0.14mL

6.79mL

1.36mL

0.68mL

13.58mL

2.72mL

1.36mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories